Abstract
Background Since the Coronavirus disease-2019 outbreak, most studies have focused on etiopathogenic aspects and treatment strategies. Acquired immunity still remains a dilemma. The aim of our study included a comprehensive analysis of patient characteristics, evaluation of antibody response, and its trend over a period of three months in recovered patients.
Methods Monocentric investigator-initiated pilot longitudinal observational study conducted by the Association Naso Sano, on a cohort of 30 COVID recovered patients based in the Umbria region, followed up from April to June 2020 for baseline blood counts, IgM and IgG trends using two different serological assays-ELISA and CLIA. The demographics, blood group, co-morbidities and treatment modalities were recorded from each patient along with an analysis of clinical profile, dates concerning symptom onset, first positive and two consecutive negative swabs using an online questionnaire followed by serological testing. Descriptive and Bivariate (Pearson correlation coefficient) statistics were conducted to detect statistically significant correlations.
Findings The study involved 30 patients with a M:F ratio of 0.57 and a distribution of mild (67%), moderate (30%) and critical (3%). Majority of the patients were healthcare workers (40%) and the mean viral shedding duration was 20.13 ± 6.17 days. The IgG levels offered long-standing protection as long as 3 months in some cases. A statistically significant, directly proportional correlation (Pearson) exists between ELISA and CLIA values for IgM. Some patients also expressed titers lower than the detection threshold and therefore a positive RT-PCR test does not necessarily guarantee a high IgG response in the recovery period.
Interpretation The data presented in our study provides a relative long-term analysis and possible explanation regarding the protection developed by patients recovered from COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is not a clinical trial. It is an observational study done on a cohort of 30 patients. This study was approved by the Institutional Research ethics committee.
Funding Statement
There was no funding source for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Association Naso Sano Ethical Review Committee, San Marino, Italy
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data of the study will be available for review.
